Giant Cell Arteritis (GCA) is well known to be a critical ischaemic disease that requires immediate medical recognition to initiate treatment and where one in five people still suffer visual loss. The immunopathophysiology has continued to be characterised, and the influencing of ageing in the development of GCA is beginning to be understood. Recent national and international guidelines have supported the directed use of cranial ultrasound to reduce diagnostic delay and improve clinical outcomes. Immediate high dose glucocorticoids remain the standard emergency treatment for GCA, with a number of targeted agents that have been shown in clinical trials to have superior clinical efficacy and steroid sparing effects. The aim of this review was to present the latest advances in GCA that have the potential to influence routine clinical practice.
摘要: 众所周知, 巨细胞动脉炎 (GCA) 是一种严重的缺血性疾病, 需要进行迅速的诊断后才能治疗, 但五分之一的患者仍会导致视力损伤。其免疫病理生理学特征正不断地被描述出来, 人们也逐渐意识到衰老对GCA进展的影响。新近的国家与国际指南中都支持直接使用颅脑超声来减少诊断过程中的延误并改善临床结局。快速使用大量糖皮质激素仍然是GCA的标准急救方法, 尽管一些靶向药物在临床实践中已经证实具有更好的临床疗效且具有类固醇的效果。本综述旨在介绍GCA的最新进展, 这可能会对日常的临床实践产生影响。.
© 2023. The Author(s).